logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
X

Xavier Durando

centre de lutte contre le cancer
H指数:39
被引数:4,824

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intrinsic validity of molecular marker(s) detection on tissue tumor DNA to predict efficacy of 177Lutetium-PSMA-617 ([177Lu]Lu-PSMA-617) treatment for castration-resistant metastatic prostate cancer (PSMA-PRED): study protocol of a prospective multicentre clinical trial

PSMA-PRED前瞻性多中心临床研究方案：组织肿瘤DNA中分子标记物检测对预测177镥-PSMA-617（[177Lu]Lu-PSMA-617）治疗去势抵抗性转移性前列腺癌疗效的固有有效性

BMC Cancer
IF3.4
2026-10-220
OAAI
Judith Passildas; Marie-Céleste Ferreira; Hakim Mahammedi; Charles Merlin; Antony Kelly; Ioana Molnar; Xavier Durando; Frédérique Penault-Llorca; Tressie Herrmann
The impact of chemotherapy-induced menopause on quality of life 30 months following treatment among young women with non-metastatic breast cancer: results from the prospective multicentre MENOCOR clinical trial

化疗诱导的绝经对非转移性乳腺癌年轻女性治疗30个月后生活质量的影响：来自前瞻性多中心MENOCOR临床 trial 的结果

Health and Quality of Life Outcomes
IF3.4
2026-10-170
OAAI
Mélanie Godiveau; Alexia Giro; Judith Passildas; Jean-Philippe Jacquin; Aude-Marie Savoye; Ioana Molnar; Catherine Abrial; Xavier Durando; Marie-Ange Mouret-Reynier
[99mTc]Tc-NTP 15 − 5, a new proteoglycan tracer for functional imaging of joint cartilage: phase I (CARSPECT)

[99mTc]Tc-NTP 15 − 5，一种用于关节软骨功能成像的新型蛋白聚糖示踪剂：I期（CARSPECT）

EJNMMI Research
IF3
2025-09-260
OA
Marion Chanchou; Emilie Thivat; Sylvain Mathieu; Sophie Levesque; Nicolas Sas; Philippe Auzeloux; Tommy Billoux; Ioana Molnar; Elodie Jouberton; Jacques Rouanet; Giovanna Fois; Lydia Maigne; Frédérique Penault-llorca; Elisabeth Miot-noirault; Xavier Durando; Florent Cachin
Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

健康相关生活质量及认知功能在寡形胶质细胞瘤幸存者中的表现：一项国际横断面调查

NEURO-ONCOLOGY
IF13.4
2025-08-011
OAAI
Boele, Florien W.; Frances, Se M.; Darlix, Amelie; Ducray, Francois; Cartalat, Stephanie; Guerdoux, Estelle; Tabouret, Emeline; Burger, Michael C.; Ryden, Isabelle; Malmstrom, Annika; Vauleon, Elodie; Kazda, Tomas; Renovanz, Mirjam; Werner, Jan-Michael; Welsh, Liam; Sanghera, Paul; Dehais, Caroline; Desideri, Isacco; McBain, Catherine; Mehta, Shaveta; Lord, Hannah; Jena, Rajesh; Foweraker, Karen; Ashkan, Keyoumars; Engelhardt, Julien; Bourg, Veronique; Herrlinger, Ulrich; Lawson McLean, Aaron; Hertler, Caroline; Haldbo-Classen, Lene; Dahlrot, Rikke H.; Noel, Georges; Durando, Xavier; Hrab, Ioana; Razis, Evangelia; Weller, Michael; Muhic, Aida; Klein, Martin
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial

基于基因组分级指数的高龄（≥70岁）高风险乳腺癌患者辅助化疗联合内分泌治疗与单纯辅助内分泌治疗的比较（ASTER 70s）：一项随机III期临床试验

lancet
IF0
2025-07-310
PRE
Etienne Brain; Olivier Mir; Emmanuelle Bourbouloux; Olivier Rigal; Jean-Marc Ferrero; Sylvie Kirscher; Djelila Allouache; Véronique D’Hondt; Aude-Marie Savoye; Xavier Durando; Francois P Duhoux; Laurence Venat-Bouvet; Emmanuel Blot; Jean-Luc Canon; Florence Rollot-Trad; Hervé Bonnefoi; Telma Roque; Jérôme Lemonnier; Aurélien Latouche; Julie Henriques; Magali Lacroix-Triki; Dewi Vernerey
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

帕博利珠单抗和伏立诺他联合治疗复发性/转移性鳞状细胞癌的疗效：一项II期篮式试验

Nature Cancer
IF28.5
2025-06-300
OAAI
Edith Borcoman; Bastien Cabarrou; Miguel Francisco; Frédéric Bigot; François Ghiringhelli; Damien Vansteene; François Legrand; Maral Halladjian; Célia Dupain; Olivia Le Saux; Clelia Coutzac; Christian Borel; Raphael Chaltiel; Benoit You; Carlos Gomez-Roca; Sophie Cousin; Elodie Coquan; Aurélien Lambert; Esma Saada-Bouzid; Xavier Durando; Mathilde Saint-Ghislain; Gianmaria Frige; Elena Guerini-Rocco; Maria Manuela Tonini; Ivan Bièche; Zahra Castel-Ajgal; Grégoire Marret; Marie-Paule Sablin; Emmanuelle Jeannot; Fabrice Andre; Thomas Filleron; Marta Jimenez; Luca Mazzarella; Nicolas Servant; Maud Kamal; Christophe Le Tourneau
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study

联合使用encorafenib和binimetinib，随后使用ipilimumab和nivolumab，与直接使用ipilimumab和nivolumab相比，在携带BRAFV600E或BRAFV600K突变的晚期黑色素瘤患者中的疗效比较（EBIN）：一项国际、开放标签、随机对照、二期研究

lancet oncology
IF0
2025-05-280
PRE
Caroline Robert; Michal Kicinski; Caroline Dutriaux; Émilie Routier; Anne-Sophie Govaerts; Emanuel Bührer; Eve-Marie Neidhardt; Xavier Durando; Barouyr Baroudjian; Philippe Saiag; Caroline Gaudy-Marqueste; Paolo A Ascierto; Ana Arance; Michelangelo Russillo; Jean-Luc Perrot; Laurent Mortier; Francois Aubin; Stéphane Dalle; Florent Grange; Eva Muñoz-Couselo; Alexander C J van Akkooi
HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
NEURO-ONCOLOGY
IF13.4
2024-11-110
PRE
Boele, Florien; Frances, Se; Darlix, Amelie; Ducray, Francois; Tabouret, Emeline; Burger, Michael; Ryden, Isabelle; Malmstrom, Annika; Vauleon, Elodie; Kazda, Tomas; Renovanz, Mirjam; Werner, Jan-Michael; Welsh, Liam; Sanghera, Paul; Dehais, Caroline; Desideri, Isacco; Mcbain, Catherine; Mehta, Shaveta; Lord, Hannah; Jena, Rajesh; Foweraker, Karen; Ashkan, Keyoumars; Engelhardt, Julien; Bourg, Veronique; Herrlinger, Ulrich; Mclean, Aaron Lawson; Hertler, Caroline; Haldbo-Classen, Lene; Dahlrot, Rikke; Noel, Georges; Durando, Xavier; Hrab, Ioana; Razis, Evangelia; Muhic, Aida; Klein, Martin
HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
NEURO-ONCOLOGY
IF13.4
2024-10-170
PRE
Boele, F. W.; Frances, S. . M.; Darlix, A.; Ducray, F.; Tabouret, E.; Burger, M. . C.; Ryden, I; Malmstrom, A.; Vauleon, E.; Kazda, T.; Renovanz, M.; Werner, J.; Welsh, L.; Sanghera, P.; Dehais, C.; Desideri, I; Mcbain, C.; Mehta, S.; Lord, H.; Jena, R.; Foweraker, K.; Ashkan, K.; Engelhardt, J.; Bourg, V; Herrlinger, U.; A Lawson, McLean; Hertler, C.; Haldbo-Classen, L.; Dahlrot, R. H.; Noel, G.; Durando, X.; Hrab, I; Razis, E.; Muhic, A.; Klein, M.
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2+BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
BREAST CANCER RESEARCH AND TREATMENT
IF3
2024-03-070
OAAI
Ginzac, Angeline; Molnar, Ioana; Durando, Xavier; De La Motte Rouge, Thibault; Petit, Thierry; D'hondt, Veronique; Campone, Mario; Bonichon-Lamichhane, Nathalie; Venat Bouvet, Laurence; Levy, Christelle; Augereau, Paule; Pistilli, Barbara; Arsene, Olivier; Nguyen, Suzanne; Jouannaud, Christelle; Cayre, Anne; Tixier, Lucie; Mahier Ait Oukhatar, Celine; Nabholtz, Jean-Marc; Penault-Llorca, Frederique; Mouret-Reynier, Marie-Ange
Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Le Saux, O.; Borel, C.; Ghiringhelli, F.; Bigot, F.; Vansteene, D.; Chaltiel, R.; Cousin, S.; Durando, X.; Coquan, E.; Abdeddaim, C.; Jeannot, E.; Rocco, E. Guerini; Frige, G.; Francisco, M.; Halladjian, M.; Kamal, M.; Legrand, F.; Jimenez, M.; Cabarrou, B.; Le Tourneau, C.
Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma - subgroup analysis of the PEVOsq basket trial
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Le Tourneau, C.; Ghiringhelli, F.; Saada, E. B.; Chaltiel, R.; Vansteene, D.; Durando, X.; You, B.; Borel, C.; Bigot, F.; Abdeddaim, C.; Marret, G.; Jeannot, E.; Rocco, E. Guerini; Frige, G.; Servant, N.; Dupain, C.; Kamal, M.; Legrand, F.; Jimenez, M.; Filleron, T.

研究方向

暂未获取到该数据
C
Catherine Abrial
H 指数:25论文数:130被引数:2,542
I
Ioana Molnar
H 指数:17论文数:116被引数:858
É
Émilie Thivat
H 指数:21论文数:92被引数:1,763
P
P. Chollet
H 指数:52论文数:349被引数:1.1万
F
Fabrice Kwiatkowski
H 指数:47论文数:259被引数:1.4万
A
Angeline Ginzac
H 指数:12论文数:50被引数:443
F
Frédérique Penault‐Llorca
H 指数:87论文数:574被引数:4.9万
M
Marie‐Ange Mouret‐Reynier
H 指数:41论文数:194被引数:7,654
P
Pierre Gimbergues
H 指数:23论文数:155被引数:2,389
J
J. Biau
H 指数:26论文数:199被引数:2,303